Student or educator? Sign up with your school email and get 6 months of Pro free.
Cited by 258

The DOI matches its Crossref record; 22 of the 22 references it cites were found in a registry or an index.

A Review on Telmisartan: A Novel, Long‐Acting Angiotensin II‐Receptor Antagonist

Wienen, Wolfgang, Entzeroth, Michael, van Meel, Jacobus C. A., Stangier, Joachim, Busch, Ulrich, Ebner, Thomas, Schmid, Jochen, Lehmann, Horst, Matzek, Kandace, Kempthorne‐Rawson, Joan, Gladigau, Volker, Hauel, Norbert H.·2000·Cardiovascular Drug Reviews

Abstract

Telmisartan is a potent, long‐lasting, nonpeptide antagonist of the angiotensin II type‐1 (AT 1) receptor that is indicated for the treatment of essential hypertension. It selectively and insurmountably inhibits stimulation of the AT 1 receptor by angiotensin II without affecting other receptor systems involved in cardiovascular regulation. Very high lipophilicity, a unique feature of telmisartan, coupled with a high volume of distribution, indicate that the compound offers the clinically important advantage of good tissue penetration. Telmisartan is not a prodrug and has a longer terminal elimination half‐life than other commercially available sartans (∼24 h), making it suitable for once‐daily dosing. The compound is not metabolized by cytochrome P450 isoenzymes and has a low risk for P450‐based drug interactions. In animal models, telmisartan exhibits pronounced cardio‐and renoprotective effects in animals with severe, essential hypertension. In clinical studies, telmisartan shows comparable antihypertensive activity to members of other major antihypertensive classes, such as ACE inhibitors, beta blockers and calcium antagonists. These trials have confirmed the placebo‐like safety and tolerability of telmisartan in hypertensive patients. Based on these data, telmisartan offers advantages over other sartans and represents an important new treatment option for hypertension.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1111/j.1527-3466.2000.tb00039.x

Cites

22 of 22 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 22 references

Cited by

See all 258

Metadata

Authors
Wienen, W., Entzeroth, M., van Meel, J. C. A., Stangier, J., Busch, U., Ebner, T., Schmid, J., Lehmann, H., Matzek, K., Kempthorne‐Rawson, J., Gladigau, V., & Hauel, N. H.
Venue
Cardiovascular Drug Reviews
Publisher
Wiley
Published
2000-06
Volume
18
Issue
2
Pages
127-154
ISSN
  • 0897-5957 (ISSN-L)
  • 1527-3466
OpenAlex
W1994696430
Cited by
258
References
22
FWCI
4.00
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: A Review on Telmisartan: A Novel, Long‐Acting Angiotensin II‐Receptor Antagonist. https://app.cochat.ai/papers/10.1111/j.1527-3466.2000.tb00039.x
The paper
Wienen, W., Entzeroth, M., van Meel, J. C. A., Stangier, J., Busch, U., Ebner, T., Schmid, J., Lehmann, H., Matzek, K., Kempthorne‐Rawson, J., Gladigau, V., & Hauel, N. H. (2000). A Review on Telmisartan: A Novel, Long‐Acting Angiotensin II‐Receptor Antagonist. Cardiovascular Drug Reviews. https://doi.org/10.1111/j.1527-3466.2000.tb00039.x

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.